Research projects

Clinical research: 

  • Local excision of early rectal cancer and premalignant lesions.
  • Surgical treatment of inflammatory bowel disease
  • Functional outcome after treatment of anal cancer

Health economy research:

  • Modeling and validating the cost and clinical pathway of colorectal cancer (crc)

Translational, multidisciplinary research (surgery, oncology, radiology, pathology, molecular biology):

  • Biomarkers -diagnostic, prognostic, predictive, monitoring – in colorectal primary cancer and in  liver metastases from colorectal cancer
  • Drug sensitivity testing of crc cell lines
  • Drug sensitivity testing of resected or biopsy samples from crc liver metastases
  • Biomarkers in anal cancer
  • Micrometastases - circulating tumor cells, disseminated tumor cells and cell free DNA – in colorectal cancer and other epithelial cancers: Methods of detection, genetic characterization, potential as prognostic and monitoring biomarkers

Planned research / long term objectives for the group:

  • Continue inclusion of patients and biobanking for one more year, continue follow-up of included patients for five years (recurrence, death), include more monitoring blood tests (liquid biopsy)
  • A lot of molecular analyses to be performed on already sampled material

Short about strategy to succeed with planned research / long term objectives:

  • Continue strong interaction and cooperation in the multidisciplinary team, creating and maintaining a real joint effort in translational research
  • Extend and improve international collaboration – aggregate patient data from many large cohorts
  • Expand the cooperation with pathologists and oncologists / surgeons in many hospitals to perform the national multicenter study on primary crc, sampling formalin fixed tumor tissue from diagnostic biobanks (pathology), creating TMA’s for automated, multiplex immunohistochemistry based study on protein biomarkers (recently established in lab)
  • Continue to improve methods for growing cancer cells in culture for testing of drug sensitivity in our own lab, and extend cooperation with Vall D’Hebron for growing cancer cells in pdx-models, as a basis for personalized medicine.
  • Establish the method of sampling liver metastases with biopsy needles, growing in cell culture followed by drug sensitivity testing
  • Extend the cooperation with the Trial unit in Dept of Oncology, OUS and with pharmaceutical companies for clinical trials

 

 
Scroll to top